SG11201401567YA - Etanercept formulations stabilized with meglumine - Google Patents

Etanercept formulations stabilized with meglumine

Info

Publication number
SG11201401567YA
SG11201401567YA SG11201401567YA SG11201401567YA SG11201401567YA SG 11201401567Y A SG11201401567Y A SG 11201401567YA SG 11201401567Y A SG11201401567Y A SG 11201401567YA SG 11201401567Y A SG11201401567Y A SG 11201401567YA SG 11201401567Y A SG11201401567Y A SG 11201401567YA
Authority
SG
Singapore
Prior art keywords
meglumine
etanercept formulations
formulations stabilized
stabilized
etanercept
Prior art date
Application number
SG11201401567YA
Inventor
Mark Manning
Brian Murphy
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of SG11201401567YA publication Critical patent/SG11201401567YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SG11201401567YA 2011-10-18 2012-10-18 Etanercept formulations stabilized with meglumine SG11201401567YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09
PCT/US2012/060743 WO2013059408A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with meglumine

Publications (1)

Publication Number Publication Date
SG11201401567YA true SG11201401567YA (en) 2014-07-30

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
SG11201401576WA SG11201401576WA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids
SG11201401563SA SG11201401563SA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions
SG11201401562RA SG11201401562RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with sodium chloride
SG11201401519RA SG11201401519RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol
SG11201401517VA SG11201401517VA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols
SG11201401567YA SG11201401567YA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with meglumine

Family Applications Before (5)

Application Number Title Priority Date Filing Date
SG11201401576WA SG11201401576WA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids
SG11201401563SA SG11201401563SA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions
SG11201401562RA SG11201401562RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with sodium chloride
SG11201401519RA SG11201401519RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol
SG11201401517VA SG11201401517VA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols

Country Status (27)

Country Link
US (21) US10293049B2 (en)
EP (6) EP2768854A4 (en)
JP (6) JP6220789B2 (en)
KR (7) KR20140091706A (en)
CN (6) CN104010657A (en)
AR (6) AR088382A1 (en)
AU (6) AU2012326171B2 (en)
BR (6) BR112014009087A2 (en)
CA (6) CA2851646A1 (en)
CY (1) CY1121843T1 (en)
DK (1) DK2768525T3 (en)
EA (6) EA028520B1 (en)
ES (1) ES2734070T3 (en)
HK (6) HK1200720A1 (en)
HR (1) HRP20191215T1 (en)
HU (1) HUE045624T2 (en)
IL (6) IL231825A0 (en)
IN (3) IN2014CN02592A (en)
LT (1) LT2768525T (en)
MX (7) MX2014004734A (en)
PL (1) PL2768525T3 (en)
PT (1) PT2768525T (en)
RS (1) RS59179B1 (en)
SG (6) SG11201401576WA (en)
SI (1) SI2768525T1 (en)
TW (6) TW201325608A (en)
WO (6) WO2013059405A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080031684A (en) 2005-06-14 2008-04-10 암젠 인코포레이티드 Self-buffering protein formulations
TW201325608A (en) * 2011-10-18 2013-07-01 Coherus Biosciences Inc Etanercept formulations stabilized with combinations of sugars and polyols
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
KR20150030704A (en) * 2012-07-09 2015-03-20 코히러스 바이오사이언시즈, 인코포레이티드 Etanercept formulations exhibiting marked reduction in sub-visible particles
PL2895188T3 (en) * 2012-09-11 2018-06-29 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
BR112015027764A2 (en) * 2013-05-02 2017-08-29 Mabxience S A ALTERNATIVE FORMULATIONS FOR TNFR FUSION POLYPEPTIDES: FC
WO2015056613A1 (en) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Stabilized polypeptide aqueous preparation
CN112107538A (en) * 2013-10-24 2020-12-22 阿斯利康(瑞典)有限公司 Stable aqueous antibody formulations
KR101712245B1 (en) 2013-11-29 2017-03-06 아레스 트레이딩 에스.에이. A liquid formulation of a fusion protein comprising TNFR and Fc region
IS3008B (en) * 2014-05-14 2018-12-15 Calor ehf A peptide or protein stabilizing formulation
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
JP6781508B2 (en) * 2014-11-18 2020-11-04 塩野義製薬株式会社 Stabilized peptide composition
AU2015371381A1 (en) 2014-12-22 2017-07-20 Ares Trading S.A. Liquid pharmaceutical composition
WO2016103034A1 (en) * 2014-12-23 2016-06-30 Drug Discovery Laboratory As Protein compositions and use thereof
US10988527B2 (en) 2014-12-31 2021-04-27 Lg Chem, Ltd. Method for preparing TNFR-Fc fusion protein containing target content of impurities
CN104694355B (en) * 2015-03-20 2016-09-28 吉林大学 Radix Puerariae liver-protection health-care wine and preparation method thereof
MX2015010517A (en) * 2015-08-13 2017-02-13 Landsteiner Scient S A De C V Etanercept composition having improved stability.
JP5938762B1 (en) * 2015-09-01 2016-06-22 日揮株式会社 Microcapsule preparation and production method thereof
CN105748414A (en) * 2016-03-02 2016-07-13 张光泉 Anti-infection micafungin freeze-drying composition and preparation method thereof
WO2017179683A1 (en) * 2016-04-15 2017-10-19 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Pharmaceutical composition containing micafungin in stabilized state
BR112019007858A2 (en) * 2016-10-21 2019-07-02 Amgen Inc pharmaceutical formulations and methods for producing the same
WO2018080196A2 (en) * 2016-10-28 2018-05-03 (주)셀트리온 Stable pharmaceutical formulation
MX2017013995A (en) * 2017-10-31 2019-05-01 Probiomed S A De C V Stable pharmaceutical formulation of a fusion protein.
AU2018374232A1 (en) * 2017-11-30 2020-07-23 Bio-Thera Solutions, Ltd. Liquid preparation of humanized antibody for treating IL-6-related disease
BR112020012399A2 (en) * 2017-12-22 2020-11-24 Samsung Bioepis Co., Ltd. liquid composition comprising vegf antagonist
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN111228225B (en) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 Recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried preparation
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
KR20220122993A (en) * 2019-11-26 2022-09-05 코메라 라이프 사이언시스, 인코포레이티드 Excipient compounds for biopolymer formulations
KR20230146579A (en) 2021-02-17 2023-10-19 아레콜 리미티드 Aqueous compositions of engineered protein constructs comprising an Fc domain
CN114788809B (en) * 2022-01-25 2023-04-14 江苏广承药业有限公司 Loratadine liquid preparation

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (en) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. STABILIZED AQUEOUS FORMULATIONS OF SMALL PEPTIDES.
KR100232688B1 (en) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 Pharmaceutical compositions for treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (en) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
MXPA02007683A (en) 2000-02-10 2002-12-13 American Home Prod Method of treating or inhibiting cellular injury or cell death.
DK1314437T3 (en) 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabilized antibody-containing preparations
WO2003102013A2 (en) * 2001-02-23 2003-12-11 Gonzalez-Villasenor Lucia Iren Methods and compositions for production of recombinant peptides
AU2003219958B2 (en) 2002-02-27 2006-01-05 Immunex Corporation Polypeptide formulation
ATE394123T1 (en) * 2003-02-28 2008-05-15 Ares Trading Sa LIQUID FORMULATIONS OF THE TUMOR NECROSIS FRACTOR BINDING PROTEIN TBP-1
JPWO2004082715A1 (en) 2003-03-20 2006-06-22 エーザイ株式会社 Concomitant medications as therapeutic agents for inflammatory bowel disease
WO2005012353A1 (en) * 2003-08-01 2005-02-10 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
CA2540858C (en) 2003-10-14 2009-12-08 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
WO2005082377A1 (en) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. INHIBITOR FOR LOWERING IN THE ACTIVITY OF ANTIHUMAN TNF-α ANTIBODY
WO2005095578A1 (en) 2004-03-05 2005-10-13 Dsm Ip Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
JP5339901B2 (en) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment and evaluation of inflammatory injury
KR101367544B1 (en) * 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 Stabilizer for protein preparation comprising meglumine and use thereof
KR20080031684A (en) * 2005-06-14 2008-04-10 암젠 인코포레이티드 Self-buffering protein formulations
NZ569108A (en) 2005-12-20 2011-09-30 Bristol Myers Squibb Co Formulations of CTLA4Ig stabilised using sugars
CN101378782A (en) 2005-12-21 2009-03-04 惠氏公司 Protein formulations with reduced viscosity and uses thereof
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
EA015992B1 (en) * 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Stabilized antibody and multivalent antibinding molecule based thereon, methods for making thereof and use such stabilized antibody
US20100016677A1 (en) 2006-03-21 2010-01-21 Eugen Oetringer Devices for and Methods of Analyzing a Physiological Condition of a Physiological Subject Based on A Workload Related Property
WO2007124082A2 (en) 2006-04-21 2007-11-01 Amgen, Inc. Buffering agents for biopharmaceutical formulations
US20080038753A1 (en) * 2006-08-01 2008-02-14 Illumigen Biosciences, Inc. Pharmaceutical manufacturing methods
WO2008045373A2 (en) 2006-10-06 2008-04-17 Amgen Inc. Stable antibody formulations
ES2925992T3 (en) * 2006-10-20 2022-10-20 Amgen Inc Stable formulations of polypeptides
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
WO2008079290A2 (en) 2006-12-21 2008-07-03 Amgen Inc Stable buffered formulations containing polypeptides
ES2541454T3 (en) 2007-03-02 2015-07-20 Wyeth Llc Use of copper and glutamate in cell cultures for polypeptide production
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
AU2008266051B2 (en) 2007-06-14 2014-07-31 Biogen Ma Inc. Antibody formulations
AU2008334099B2 (en) * 2007-11-30 2014-07-24 Abbvie Biotechnology Ltd. Protein formulations and methods of making same
JP6078217B2 (en) * 2008-01-15 2017-02-08 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Powdered protein composition and method for producing the same
MX2010009398A (en) 2008-02-29 2010-11-12 Biogen Idec Inc Purified immunoglobulin fusion proteins and methods of their purification.
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
CN104059955A (en) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 Production Of Proteins In Glutamine-free Cell Culture Media
EP2490780A4 (en) 2009-10-20 2014-04-09 Merck Sharp & Dohme Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
SG185038A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell culture medium
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
EP2598167B1 (en) 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
CN103097516B (en) 2010-08-31 2015-09-09 菲仕兰品牌公司 Eukaryotic cell substratum
CN103379949B (en) 2010-10-11 2016-09-14 艾伯维巴哈马有限公司 Method for purifying proteins
AU2012244764B2 (en) 2011-04-20 2016-10-13 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
KR20140054002A (en) 2011-06-29 2014-05-08 인사이트 비젼 인코포레이티드 Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
EA026226B1 (en) 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. ARGININE-FREE Fc-FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF
EP2837680B1 (en) 2011-07-01 2020-02-26 Amgen Inc. Mammalian cell culture
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
AU2012282960A1 (en) 2011-07-08 2014-01-16 Merck Sharp & Dohme Corp. Method for purifying Fc-fusion protein
EP2753634B1 (en) 2011-08-17 2017-11-01 Ares Trading S.A. Method for preparing active form of tnfr-fc fusion protein
TW201325608A (en) * 2011-10-18 2013-07-01 Coherus Biosciences Inc Etanercept formulations stabilized with combinations of sugars and polyols
PL2895188T3 (en) 2012-09-11 2018-06-29 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield

Also Published As

Publication number Publication date
CA2851651A1 (en) 2013-04-25
MX2014004732A (en) 2015-05-15
JP2014530255A (en) 2014-11-17
EP2768531A4 (en) 2015-03-11
EP2768535A1 (en) 2014-08-27
US20180193463A1 (en) 2018-07-12
EP2768531A1 (en) 2014-08-27
CY1121843T1 (en) 2020-07-31
US20180125982A1 (en) 2018-05-10
US11129876B2 (en) 2021-09-28
MX2014004728A (en) 2015-05-15
HRP20191215T1 (en) 2019-10-04
DK2768525T3 (en) 2019-07-22
US20190290768A1 (en) 2019-09-26
US20130108633A1 (en) 2013-05-02
AR088383A1 (en) 2014-05-28
TW201325608A (en) 2013-07-01
JP6104922B2 (en) 2017-03-29
RS59179B1 (en) 2019-10-31
JP6199298B2 (en) 2017-09-20
TWI644681B (en) 2018-12-21
MX2014004734A (en) 2015-05-15
US10980884B2 (en) 2021-04-20
US10293049B2 (en) 2019-05-21
CN104010657A (en) 2014-08-27
IL231826A0 (en) 2014-05-28
US11135267B2 (en) 2021-10-05
HK1200718A1 (en) 2015-08-14
EA025663B1 (en) 2017-01-30
US10772963B2 (en) 2020-09-15
JP2014530863A (en) 2014-11-20
TW201325606A (en) 2013-07-01
US20190184017A1 (en) 2019-06-20
US20190290765A1 (en) 2019-09-26
US9302002B2 (en) 2016-04-05
AU2012326171A1 (en) 2014-04-24
EP2768535A4 (en) 2015-03-11
EP2768525A1 (en) 2014-08-27
KR20140091707A (en) 2014-07-22
JP2014530864A (en) 2014-11-20
EA026410B1 (en) 2017-04-28
EA201490815A1 (en) 2014-09-30
CA2851635A1 (en) 2013-04-25
BR112014009131A8 (en) 2017-06-20
AU2012326170A1 (en) 2014-04-24
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
CN104010658A (en) 2014-08-27
TW201325611A (en) 2013-07-01
KR20140079491A (en) 2014-06-26
IN2014CN02527A (en) 2015-06-26
AU2012326171B2 (en) 2017-03-09
EP2768854A4 (en) 2015-03-11
MX2014004725A (en) 2015-02-05
AU2012326084A1 (en) 2014-04-17
MX367054B (en) 2019-08-02
US10987405B2 (en) 2021-04-27
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (en) 2013-04-25
BR112014009131A2 (en) 2017-06-13
JP2014530254A (en) 2014-11-17
BR112014009031A2 (en) 2017-05-09
US20190314498A1 (en) 2019-10-17
US9770510B2 (en) 2017-09-26
CA2851628A1 (en) 2013-04-25
CN104010654A (en) 2014-08-27
CN104011073B (en) 2017-08-25
SG11201401576WA (en) 2014-10-30
BR112014009073A2 (en) 2017-05-09
US20190314500A1 (en) 2019-10-17
EA028520B1 (en) 2017-11-30
AU2012326168A1 (en) 2014-04-24
AU2012326082B2 (en) 2016-12-15
AR088380A1 (en) 2014-05-28
EP2768533A4 (en) 2015-03-11
MX2019009176A (en) 2019-10-07
KR20140083037A (en) 2014-07-03
IN2014CN02592A (en) 2015-09-04
US20190298837A1 (en) 2019-10-03
AU2012326080B2 (en) 2017-02-16
KR20140097184A (en) 2014-08-06
EA027325B1 (en) 2017-07-31
HK1200851A1 (en) 2015-08-14
US20190290766A1 (en) 2019-09-26
US9801942B2 (en) 2017-10-31
IL231827A0 (en) 2014-05-28
LT2768525T (en) 2019-09-25
SI2768525T1 (en) 2019-10-30
EP2768525A4 (en) 2015-07-15
US20200405865A1 (en) 2020-12-31
AU2012326082A1 (en) 2014-04-24
WO2013059406A1 (en) 2013-04-25
IN2014CN02591A (en) 2015-06-26
BR112014009146A8 (en) 2017-06-20
KR102163150B1 (en) 2020-10-08
PT2768525T (en) 2019-07-17
AU2012326168B2 (en) 2016-12-15
WO2013059407A1 (en) 2013-04-25
HK1200721A1 (en) 2015-08-14
SG11201401562RA (en) 2014-09-26
KR20140091706A (en) 2014-07-22
HUE045624T2 (en) 2020-01-28
CA2851642A1 (en) 2013-04-25
KR102068462B1 (en) 2020-01-22
EP2768532A4 (en) 2015-03-11
US20190290767A1 (en) 2019-09-26
EP2768854A1 (en) 2014-08-27
MX2014004733A (en) 2015-05-15
TW201325607A (en) 2013-07-01
HK1200720A1 (en) 2015-08-14
EA201490804A1 (en) 2014-09-30
US20130108632A1 (en) 2013-05-02
MX2014004726A (en) 2015-05-15
TW201325610A (en) 2013-07-01
EP2768532A1 (en) 2014-08-27
KR20140091705A (en) 2014-07-22
US9943601B2 (en) 2018-04-17
EP2768525B1 (en) 2019-06-19
AR088379A1 (en) 2014-05-28
CN103998060A (en) 2014-08-20
CN103998060B (en) 2016-12-21
JP6220789B2 (en) 2017-10-25
US20190314499A1 (en) 2019-10-17
JP2014530862A (en) 2014-11-20
EA201490803A1 (en) 2014-09-30
TW201325609A (en) 2013-07-01
TWI595883B (en) 2017-08-21
CA2851639A1 (en) 2013-04-25
US10213508B2 (en) 2019-02-26
IL231825A0 (en) 2014-05-28
AU2012326170B2 (en) 2016-12-22
IL231824A0 (en) 2014-05-28
EP2768533A1 (en) 2014-08-27
PL2768525T3 (en) 2019-10-31
EA201490801A1 (en) 2014-09-30
IL231828A0 (en) 2014-05-28
JP6113176B2 (en) 2017-04-12
CN104010654B (en) 2017-10-27
AU2012326080A1 (en) 2014-04-24
EA025267B1 (en) 2016-12-30
SG11201401519RA (en) 2014-07-30
BR112014009146A2 (en) 2017-06-13
BR112014009087A2 (en) 2017-04-18
AR088381A1 (en) 2014-05-28
US20160317667A1 (en) 2016-11-03
CN103998061A (en) 2014-08-20
ES2734070T3 (en) 2019-12-04
HK1200719A1 (en) 2015-08-14
US20130101640A1 (en) 2013-04-25
AR088460A1 (en) 2014-06-11
HK1200722A1 (en) 2015-08-14
US10376588B2 (en) 2019-08-13
IL231829A0 (en) 2014-05-28
US9393305B2 (en) 2016-07-19
EA201490802A1 (en) 2014-08-29
BR112014009022A2 (en) 2017-05-02
WO2013059408A1 (en) 2013-04-25
JP2014530256A (en) 2014-11-17
CN104011073A (en) 2014-08-27
JP6220788B2 (en) 2017-10-25
CA2851639C (en) 2020-12-29
JP6110393B2 (en) 2017-04-05
CA2851646A1 (en) 2013-04-25
SG11201401517VA (en) 2014-09-26
WO2013059412A1 (en) 2013-04-25
US20160199489A1 (en) 2016-07-14
SG11201401563SA (en) 2014-09-26
AU2012326084B2 (en) 2016-12-15
EA201490817A1 (en) 2014-09-30
US20190216930A1 (en) 2019-07-18
KR20200008021A (en) 2020-01-22
US10980885B2 (en) 2021-04-20
TWI619504B (en) 2018-04-01
US10888619B2 (en) 2021-01-12
AR088382A1 (en) 2014-05-28
US20130101584A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
HK1200722A1 (en) Etanercept formulations stabilized with meglumine
IL276234B (en) Antibody formulations
IL229233A0 (en) Anti-c-met antibody formulations
EP2747556A4 (en) Pyrethroid formulations
ZA201402148B (en) Coolant formulations
EP2786976A4 (en) Monolithic composition
PL2753311T3 (en) Antioxidant formulations
HK1197193A1 (en) Sunscreen formulations
ZA201308061B (en) Otamixaban formulations with improved stability
GB201110278D0 (en) Formulations
GB201111578D0 (en) Pharmeutical formulations
GB201111013D0 (en) Formulations
GB201107626D0 (en) Formulations
GB201107627D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201105360D0 (en) Formulations
GB201104049D0 (en) Formulations
GB201104048D0 (en) Formulations
GB201102795D0 (en) Formulations